Lister Martin F, Sharkey John, Sawatzky Deborah A, Hodgkiss Joseph P, Davidson Donald J, Rossi Adriano G, Finlayson Keith
MRC Centre for Inflammation Research, The Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK.
J Inflamm (Lond). 2007 Mar 16;4:5. doi: 10.1186/1476-9255-4-5.
The inflammatory process, orchestrated against a variety of injurious stimuli, is composed of three inter-related phases; initiation, propagation and resolution. Understanding the interplay between these three phases and harnessing the beneficial properties of inflammation whilst preventing its damaging effects, will undoubtedly lead to the advent of much needed therapies, particularly in chronic disease states. The P2X7 receptor (P2X7R) is increasingly recognised as an important cell surface regulator of several key inflammatory molecules including IL-1beta, IL-18, TNF-alpha and IL-6. Moreover, as P2X7R-dependent cytokine production is driven by activating the inflammasome, antagonists of this receptor are likely to have therapeutic potential as novel anti-inflammatory therapies. The function of the P2X7R in inflammation, immunity and its potential role in disease will be reviewed and discussed.
起始、传播和消退。了解这三个阶段之间的相互作用,并利用炎症的有益特性同时预防其破坏作用,无疑将带来急需的治疗方法,特别是在慢性疾病状态下。P2X7受体(P2X7R)越来越被认为是包括白细胞介素-1β(IL-1β)、白细胞介素-18(IL-18)、肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)在内的几种关键炎症分子的重要细胞表面调节因子。此外,由于依赖P2X7R的细胞因子产生是由炎性小体激活驱动的,该受体的拮抗剂作为新型抗炎疗法可能具有治疗潜力。将对P2X7R在炎症、免疫中的功能及其在疾病中的潜在作用进行综述和讨论。